Your browser is no longer supported. Please, upgrade your browser.
OncoCyte Corporation
Index- P/E- EPS (ttm)-0.36 Insider Own0.40% Shs Outstand89.76M Perf Week5.26%
Market Cap321.47M Forward P/E- EPS next Y-0.41 Insider Trans0.00% Shs Float82.12M Perf Month-13.04%
Income-27.50M PEG- EPS next Q-0.12 Inst Own63.50% Short Float2.80% Perf Quarter-35.48%
Sales4.20M P/S76.54 EPS this Y-4.60% Inst Trans0.97% Short Ratio3.79 Perf Half Y-32.14%
Book/sh1.14 P/B2.98 EPS next Y-5.30% ROA-26.20% Target Price9.00 Perf Year119.35%
Cash/sh0.50 P/C6.75 EPS next 5Y- ROE-39.70% 52W Range1.41 - 6.57 Perf YTD42.26%
Dividend- P/FCF- EPS past 5Y-1.90% ROI-75.50% 52W High-48.25% Beta1.82
Dividend %- Quick Ratio2.50 Sales past 5Y- Gross Margin-13.60% 52W Low141.13% ATR0.19
Employees51 Current Ratio2.50 Sales Q/Q1319.60% Oper. Margin- RSI (14)43.47 Volatility5.57% 5.09%
OptionableYes Debt/Eq0.02 EPS Q/Q15.50% Profit Margin- Rel Volume0.46 Prev Close3.40
ShortableYes LT Debt/Eq0.01 EarningsAug 10 AMC Payout- Avg Volume605.90K Price3.40
Recom1.80 SMA20-0.53% SMA50-9.90% SMA200-27.31% Volume277,877 Change0.00%
Mar-17-21Resumed Needham Buy $8
Jan-07-21Upgrade The Benchmark Company Speculative Buy → Buy $6
Dec-16-20Upgrade Piper Sandler Neutral → Overweight $2 → $4
Nov-30-20Initiated BTIG Research Buy $5
Nov-10-20Initiated KeyBanc Capital Markets Overweight $5
Jul-30-20Reiterated The Benchmark Company Speculative Buy $7 → $6
Jul-01-20Downgrade Piper Sandler Overweight → Neutral
Jun-30-20Downgrade Chardan Capital Markets Buy → Neutral $2
Jun-02-20Initiated Needham Buy $4
Feb-13-19Initiated Piper Jaffray Overweight $6
Jan-29-19Upgrade Janney Neutral → Buy
Dec-19-18Resumed Lake Street Buy
Oct-26-21 04:05PM  
Oct-08-21 09:46AM  
Oct-07-21 08:00AM  
Sep-30-21 08:00AM  
Sep-20-21 11:35AM  
Sep-16-21 08:00AM  
Sep-13-21 08:00AM  
Sep-07-21 04:05PM  
Aug-23-21 09:13AM  
Aug-18-21 08:49AM  
Aug-17-21 08:00AM  
Aug-10-21 04:01PM  
Aug-09-21 08:00AM  
Aug-03-21 03:00PM  
Jul-27-21 10:35AM  
Jul-08-21 05:34AM  
Jun-22-21 08:00AM  
Jun-15-21 08:03AM  
Jun-03-21 08:00AM  
Jun-01-21 08:00AM  
May-24-21 05:26AM  
May-17-21 04:01PM  
May-06-21 08:00AM  
May-04-21 04:01PM  
Apr-28-21 04:31PM  
Apr-19-21 08:00AM  
Apr-14-21 09:02AM  
Apr-10-21 01:31PM  
Apr-06-21 04:05PM  
Mar-23-21 01:44AM  
Mar-16-21 04:01PM  
Mar-15-21 08:00AM  
Mar-09-21 08:00AM  
Mar-04-21 08:00AM  
Mar-03-21 04:01PM  
Feb-25-21 08:00AM  
Feb-23-21 04:05PM  
Feb-16-21 04:05PM  
Feb-09-21 04:05PM  
Feb-05-21 06:06PM  
Feb-04-21 04:05PM  
Feb-02-21 09:35AM  
Jan-29-21 08:30PM  
Jan-28-21 08:00AM  
Jan-20-21 04:08PM  
Jan-12-21 06:21PM  
Dec-17-20 08:50AM  
Dec-15-20 10:48AM  
Dec-07-20 04:05PM  
Nov-30-20 05:38PM  
Nov-18-20 04:05PM  
Nov-17-20 11:55PM  
Nov-16-20 05:49AM  
Nov-12-20 04:05PM  
Nov-09-20 04:05PM  
Nov-05-20 11:23AM  
Nov-02-20 08:00AM  
Oct-28-20 08:00AM  
Oct-20-20 05:21PM  
Oct-14-20 08:00AM  
Oct-08-20 08:00AM  
Oct-01-20 08:00AM  
Sep-15-20 07:59AM  
Sep-14-20 08:00AM  
Sep-09-20 08:00AM  
Sep-03-20 08:00AM  
Sep-01-20 11:00AM  
Aug-27-20 08:00AM  
Aug-13-20 04:05PM  
Aug-11-20 08:00AM  
Aug-07-20 08:49AM  
Jul-29-20 06:45PM  
Jul-20-20 04:05PM  
Jul-16-20 08:00AM  
Jul-14-20 08:00AM  
Jul-02-20 10:54AM  
Jun-30-20 07:41AM  
Jun-29-20 04:05PM  
Jun-17-20 10:32AM  
Jun-15-20 08:00AM  
Jun-10-20 04:18PM  
May-13-20 05:51PM  
May-12-20 04:05PM  
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del Nord-Ovest of Pisa to evaluate DetermaIO as a biomarker for immunotherapy response in metastatic colorectal cancer; and Echelon Diagnostics, Inc. The company was founded in 2009 and is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANDREWS RONALD ASBURYChief Executive OfficerJul 01Option Exercise0.0065,0000259,046Jul 02 09:32 PM
ANDREWS RONALD ASBURYChief Executive OfficerMay 07Option Exercise0.00106,2210219,919Jul 02 01:59 PM
Levine Mitchell SChief Financial OfficerApr 28Option Exercise0.0020,000066,700Apr 30 07:09 PM
ANDREWS RONALD ASBURYChief Executive OfficerMar 19Buy4.7911,00052,702113,698Mar 22 05:17 PM
BROADWOOD PARTNERS, L.P.10% OwnerFeb 05Buy4.50600,0002,700,00016,776,484Feb 09 05:21 PM
BROADWOOD PARTNERS, L.P.10% OwnerJan 20Buy3.421,460,2804,999,99916,176,484Jan 22 04:28 PM
KINGSLEY ALFRED DDirectorDec 28Option Exercise1.3465,27187,463384,111Dec 28 09:46 PM
KINGSLEY ALFRED DDirectorDec 23Option Exercise1.341,2371,658319,740Dec 28 09:46 PM
KINGSLEY ALFRED DDirectorDec 23Sale2.559002,295318,840Dec 28 09:46 PM
KINGSLEY ALFRED DDirectorDec 22Option Exercise1.3410,51614,091326,155Dec 23 09:12 PM
KINGSLEY ALFRED DDirectorDec 21Option Exercise1.3447,97664,288350,787Dec 23 09:12 PM
KINGSLEY ALFRED DDirectorDec 21Sale2.545,14813,076315,639Dec 23 09:12 PM